Letrozole
- Generic Name
- Letrozole
- Brand Names
- Femara, Kisqali Femara Co-pack
- Drug Type
- Small Molecule
- Chemical Formula
- C17H11N5
- CAS Number
- 112809-51-5
- Unique Ingredient Identifier
- 7LKK855W8I
- Background
Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor first described in the literature in 1990. It is a third generation aromatase inhibitor like exemestane and anastrozole, meaning it does not significantly affect cortisol, aldosterone, and thyroxine.
Letrozole was granted FDA approval on 25 July 1997.
- Indication
Letrozole is indicated to treat postmenopausal women with hormone receptor (HR) positive early breast cancer, postmenopausal women with early breast cancer who have periviously been treated with tamoxifen, and postmenopausal women with HR+ or unknown advanced breast cancer. Letrozole, given with ribociclib, is indicated to treat pre, peri, and postmenopausal...
- Associated Conditions
- Advanced Breast Cancer, Anovulatory cycle, Epithelial Ovarian Cancer, HR+, HER2-, Advanced Breast Cancer, Stage I Breast Cancer, Metastatic HR + HER2 - breast cancer
- Associated Therapies
- -
A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-02-24
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Beta Pharma (Suzhou) Co., Ltd.
- Target Recruit Count
- 224
- Registration Number
- NCT04282031
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Association of Survival With Maintenance Therapy in Patients With Metastatic Breast Cancer After First-line Chemotherapy
- First Posted Date
- 2020-02-06
- Last Posted Date
- 2020-02-10
- Target Recruit Count
- 760
- Registration Number
- NCT04258163
- Locations
- 🇨🇳
First People's Hospital of Foshan, Foshan, Guangdong, China
🇨🇳Sun Yat-sen Memorial Hospital,Sun Yat-sen University, Guangzhou, Guangdong, China
🇨🇳Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study
- First Posted Date
- 2020-02-05
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 4
- Registration Number
- NCT04256941
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Different Protocols in Ovarian Stimulation in Intracytoplasmic Sperm Injection Cycles
- Conditions
- Interventions
- First Posted Date
- 2019-12-10
- Last Posted Date
- 2022-11-30
- Lead Sponsor
- Assiut University
- Registration Number
- NCT04193930
- Locations
- 🇪🇬
Women Health Hospital - Assiut university, Assiut, Egypt
Phase 2 Window Study of SAR439859 (Amcenestrant) Versus Letrozole in Post-menopausal Patients With ER+, HER2- Pre-operative Post-menopausal Primary Breast Cancer
- First Posted Date
- 2019-12-09
- Last Posted Date
- 2022-06-29
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 105
- Registration Number
- NCT04191382
- Locations
- 🇺🇸
Investigational Site Number 8400010, Los Angeles, California, United States
🇺🇸Investigational Site Number 8400005, Lincoln, Nebraska, United States
🇺🇸Investigational Site Number 8400012, Tacoma, Washington, United States
Pharmacokinetics and Hepatic Safety of EGCG
- Conditions
- Interventions
- First Posted Date
- 2019-11-26
- Last Posted Date
- 2023-06-05
- Lead Sponsor
- Yale University
- Target Recruit Count
- 39
- Registration Number
- NCT04177693
- Locations
- 🇺🇸
Johns Hopkins Medicine, Baltimore, Maryland, United States
Real-world Treatment Patterns and Effectiveness of Palbociclib and AI Therapy
- Conditions
- Interventions
- First Posted Date
- 2019-11-25
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 813
- Registration Number
- NCT04176354
- Locations
- 🇺🇸
Pfizer, New York, New York, United States
IUI With Letrozole Versus in Natural Cycle
- Conditions
- Interventions
- First Posted Date
- 2019-11-19
- Last Posted Date
- 2024-02-07
- Lead Sponsor
- Peking University Third Hospital
- Target Recruit Count
- 982
- Registration Number
- NCT04169451
- Locations
- 🇨🇳
Peking University Third Hospital, Beijing, Beijing, China
Palbociclib Plus Letrozole in Hormone Receptor Positive Residual Disease After Neoadjuvant Chemotherapy
- First Posted Date
- 2019-10-17
- Last Posted Date
- 2022-10-25
- Lead Sponsor
- SOLTI Breast Cancer Research Group
- Target Recruit Count
- 22
- Registration Number
- NCT04130152
- Locations
- 🇪🇸
Hospital General de Catalunya, Barcelona, Spain
🇪🇸ICO Hospitalet, Barcelona, Spain
🇪🇸Hospital 12 de octubre, Madrid, Spain
The Effects of Short-term Preoperative Treatment With Hormonal Therapy on Gene Profiles in Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-10-16
- Last Posted Date
- 2024-05-07
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 30
- Registration Number
- NCT04129216
- Locations
- 🇺🇸
Johns Hopkins Bayview Hospital, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.